Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation

Indian Journal of Cancer
F YilmazF Vural

Abstract

About 20-25% of the testicular germ cell tumors (TGCT) are relapsed or refractory after first line therapy and optimal treatment for this group is poorly defined. We aimed to analyze the efficacy and safety of autologous stem cell transplantation (ASCT) in this patient group.Material and. 19 patients with 28 ASCT were retrospectively analyzed. All the patients were treated with BEP (Bleomycin, etoposide, cisplatin) as first line therapy and TIP(paclitexalifosfamide, cisplatin) was given as salvage chemotherapy. Stem cell collection was performed with TIP and granulocyte stimulating factor. ASCT was performed with carboplatin(700mg/m2) and etoposite(750mg /m 2). The results were provided as median(min-max). P<0.05 was accepted as statistical significant level. After ASCT, complete(CR) and partial remission (PR) rates were 47.3% and 31 .5% respectively. The median overall survival(OS) and progression free survival (PFS) were 18(0-37.4 months) and 7(0-15months) months respectively. Estimated 2-year OS was 47.4% and PFS was 35.3%. Grade 3/4 toxicities including diarrhea, mucositis, and toxic hepatitis were observed in 5 patients. Only one patient died due to complication of transplantation. Although the number of the patients in th...Continue Reading

References

Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BeyerW Siegert
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel A VaenaLawrence H Einhorn
Jun 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-L PicoUNKNOWN European Group for Blood and Marrow Transplantation (EBMT)
Jul 27, 2007·The New England Journal of Medicine·Lawrence H EinhornRafat Abonour
Feb 14, 2008·JAMA : the Journal of the American Medical Association·Darren R FeldmanRobert J Motzer
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN International Prognostic Factors Study GroupChristian K Kollmannsberger
Mar 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchJörg Beyer
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchJörg Beyer
Oct 14, 2014·Urologic Oncology·Brent O'Carrigan, Peter Grimison
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nabil AdraLawrence H Einhorn

❮ Previous
Next ❯

Citations

Oct 15, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Ismail ErturkFikret Arpacı

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.